Could Prasinezumab be reducing motor progression in the PASADENA Open-Label Extension? -Rallying 23

Rallying to the Challenge 2023 - DAY 2
Dr Patrik Brundin and Matthew May, Roche
In this talk, Dr Patrik Brundin and Matthew May review the results of the open-label extension to the Phase 2 PASADENA clinical trial of prasinezumab. Prasinezumab is an immunotherapy developed by Roche that is suggested to target alpha-synuclein aggregation in Parkinson's - a driver of disease progression. Although the original study did not meet its primary efficacy outcome, this extension suggests prasinezumab may slow or delay the worsening of motor symptoms in people with Parkinson's; however, these results are exploratory and need additional research.
This talk was given as a part of the Rallying to the Challenge meeting, hosted by Cure Parkinson's and the Van Andel Institute in Grand Rapids, Michigan on September 27-28, 2023. Rallying to the Challenge is a meeting designed for and by people with Parkinson’s, advocates, and care partners to explore how the Parkinson’s community can impact and accelerate research. It is a part of the larger Grand Challenges in Parkinson's Disease meeting, an annual scientific symposium for Parkinson's research.

[@TheLittleEconomist]

For the record, I am a 56 year old female who was diagnosed last year. I’ve had minor tremors for about 5 years. My husband made me go to the doctor to get them checked out. we married last year.

[@TheLittleEconomist]

The results are very interesting especially those relating to possible alpha synuclean reduction. I wonder if exercise could be playing a similar role?
I would also like to see cohort demographics, particularly age, weight, level of exercise and sex. As a small female who is does a lot of sport and younger in Parkinson’s terms, I would like to know how well this works.